Cargando…
Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare disorder caused by mutations in TYMP, leading to a deficiency in thymidine phosphorylase and a subsequent systemic accumulation of thymidine and 2’-deoxyuridine. Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141342/ https://www.ncbi.nlm.nih.gov/pubmed/32183169 http://dx.doi.org/10.3390/jcm9030788 |
_version_ | 1783519177409036288 |
---|---|
author | Kipper, Karin Hecht, Max Antunes, Natalicia J. Fairbanks, Lynette D. Levene, Michelle Kalkan Uçar, Sema Schaefer, Andrew Blakely, Emma L. Bax, Bridget E. |
author_facet | Kipper, Karin Hecht, Max Antunes, Natalicia J. Fairbanks, Lynette D. Levene, Michelle Kalkan Uçar, Sema Schaefer, Andrew Blakely, Emma L. Bax, Bridget E. |
author_sort | Kipper, Karin |
collection | PubMed |
description | Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare disorder caused by mutations in TYMP, leading to a deficiency in thymidine phosphorylase and a subsequent systemic accumulation of thymidine and 2’-deoxyuridine. Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is under clinical development as an enzyme replacement therapy for MNGIE. Bioanalytical methods were developed according to regulatory guidelines for the quantification of thymidine and 2’-deoxyuridine in plasma and urine using liquid chromatography-tandem mass spectrometry (LC–MS/MS) for supporting the pharmacodynamic evaluation of EE-TP. Samples were deproteinized with 5% perchloric acid (v/v) and the supernatants analyzed using a Hypercarb column (30 × 2.1 mm, 3 µm), with mobile phases of 0.1% formic acid in methanol and 0.1% formic acid in deionized water. Detection was conducted using an ion-spray interface running in positive mode. Isotopically labelled thymidine and 2’-deoxyuridine were used as internal standards. Calibration curves for both metabolites showed linearity (r > 0.99) in the concentration ranges of 10–10,000 ng/mL for plasma, and 1–50 µg/mL for urine, with method analytical performances within the acceptable criteria for quality control samples. The plasma method was successfully applied to the diagnosis of two patients with MNGIE and the quantification of plasma metabolites in three patients treated with EE-TP. |
format | Online Article Text |
id | pubmed-7141342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71413422020-04-10 Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy Kipper, Karin Hecht, Max Antunes, Natalicia J. Fairbanks, Lynette D. Levene, Michelle Kalkan Uçar, Sema Schaefer, Andrew Blakely, Emma L. Bax, Bridget E. J Clin Med Article Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare disorder caused by mutations in TYMP, leading to a deficiency in thymidine phosphorylase and a subsequent systemic accumulation of thymidine and 2’-deoxyuridine. Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is under clinical development as an enzyme replacement therapy for MNGIE. Bioanalytical methods were developed according to regulatory guidelines for the quantification of thymidine and 2’-deoxyuridine in plasma and urine using liquid chromatography-tandem mass spectrometry (LC–MS/MS) for supporting the pharmacodynamic evaluation of EE-TP. Samples were deproteinized with 5% perchloric acid (v/v) and the supernatants analyzed using a Hypercarb column (30 × 2.1 mm, 3 µm), with mobile phases of 0.1% formic acid in methanol and 0.1% formic acid in deionized water. Detection was conducted using an ion-spray interface running in positive mode. Isotopically labelled thymidine and 2’-deoxyuridine were used as internal standards. Calibration curves for both metabolites showed linearity (r > 0.99) in the concentration ranges of 10–10,000 ng/mL for plasma, and 1–50 µg/mL for urine, with method analytical performances within the acceptable criteria for quality control samples. The plasma method was successfully applied to the diagnosis of two patients with MNGIE and the quantification of plasma metabolites in three patients treated with EE-TP. MDPI 2020-03-13 /pmc/articles/PMC7141342/ /pubmed/32183169 http://dx.doi.org/10.3390/jcm9030788 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kipper, Karin Hecht, Max Antunes, Natalicia J. Fairbanks, Lynette D. Levene, Michelle Kalkan Uçar, Sema Schaefer, Andrew Blakely, Emma L. Bax, Bridget E. Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title | Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title_full | Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title_fullStr | Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title_full_unstemmed | Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title_short | Quantification of Plasma and Urine Thymidine and 2’-Deoxyuridine by LC-MS/MS for the Pharmacodynamic Evaluation of Erythrocyte Encapsulated Thymidine Phosphorylase in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy |
title_sort | quantification of plasma and urine thymidine and 2’-deoxyuridine by lc-ms/ms for the pharmacodynamic evaluation of erythrocyte encapsulated thymidine phosphorylase in patients with mitochondrial neurogastrointestinal encephalomyopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141342/ https://www.ncbi.nlm.nih.gov/pubmed/32183169 http://dx.doi.org/10.3390/jcm9030788 |
work_keys_str_mv | AT kipperkarin quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT hechtmax quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT antunesnataliciaj quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT fairbankslynetted quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT levenemichelle quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT kalkanucarsema quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT schaeferandrew quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT blakelyemmal quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy AT baxbridgete quantificationofplasmaandurinethymidineand2deoxyuridinebylcmsmsforthepharmacodynamicevaluationoferythrocyteencapsulatedthymidinephosphorylaseinpatientswithmitochondrialneurogastrointestinalencephalomyopathy |